How Analysts Feel About Atricure Inc (NASDAQ:ATRC) After Increase in Sellers?

October 2, 2018 - By olga

AtriCure, Inc. (NASDAQ:ATRC) Logo

Investors sentiment increased to 1.38 in Q2 2018. Its up 0.60, from 0.78 in 2018Q1. It increased, as 7 investors sold AtriCure, Inc. shares while 30 reduced holdings. 13 funds opened positions while 38 raised stakes. 28.28 million shares or 5.97% more from 26.69 million shares in 2018Q1 were reported.
Quantum Capital owns 114,345 shares or 1.19% of their US portfolio. Tudor Inv Corp Et Al invested 0.03% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC). Moreover, Emerald Mutual Fund Advisers has 0.42% invested in AtriCure, Inc. (NASDAQ:ATRC). Vident Investment Advisory Ltd stated it has 23,967 shares. Loomis Sayles And L P invested 0.05% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC). First Manhattan Company holds 0% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC) for 1,000 shares. Utah-based Wasatch Advisors Incorporated has invested 0.12% in AtriCure, Inc. (NASDAQ:ATRC). The Ohio-based Keybank Association Oh has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Moreover, Us Bank & Trust De has 0% invested in AtriCure, Inc. (NASDAQ:ATRC). 11,294 were reported by Metropolitan Life. Campbell And Inv Adviser Lc owns 11,139 shares for 0.23% of their portfolio. Price T Rowe Inc Md invested in 2.39M shares. Northern Trust reported 442,001 shares stake. 2,794 are held by Ameritas Investment Partners. 109,861 were reported by Ameriprise Fincl Incorporated.

Since May 7, 2018, it had 0 buys, and 4 insider sales for $493,930 activity. On Tuesday, May 15 the insider Noznesky Justin J sold $92,200. 10,000 shares were sold by Krell Elizabeth D, worth $228,200 on Monday, May 7.

The stock of Atricure Inc (NASDAQ:ATRC) registered an increase of 1.78% in short interest. ATRC’s total short interest was 2.10 million shares in October as published by FINRA. Its up 1.78% from 2.06M shares, reported previously. With 152,500 shares average volume, it will take short sellers 14 days to cover their ATRC’s short positions. The short interest to Atricure Inc’s float is 6.89%.

The stock decreased 2.53% or $0.88 during the last trading session, reaching $33.97. About 47,333 shares traded. AtriCure, Inc. (NASDAQ:ATRC) has risen 68.55% since October 2, 2017 and is uptrending. It has outperformed by 52.93% the S&P500.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company has market cap of $1.20 billion. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It currently has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Among 4 analysts covering Atricure (NASDAQ:ATRC), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Atricure had 7 analyst reports since April 27, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, June 27 by Canaccord Genuity. The company was maintained on Friday, April 27 by Stifel Nicolaus. On Friday, April 27 the stock rating was maintained by Needham with “Buy”. Stifel Nicolaus maintained it with “Buy” rating and $32 target in Wednesday, June 27 report. Needham maintained AtriCure, Inc. (NASDAQ:ATRC) on Wednesday, June 27 with “Buy” rating. Needham maintained the shares of ATRC in report on Monday, June 18 with “Buy” rating.

Another recent and important AtriCure, Inc. (NASDAQ:ATRC) news was published by Benzinga.com which published an article titled: “The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping …” on September 21, 2018.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>